Posted by Michael Wonder on 13 Nov 2020
Health Canada extends approval of Imvamune to immunisation against monkeypox and orthopox viruses
12 November 2020 - Bavarian Nordic announced today that Health Canada has expanded the approval of the Company’s non-replicating smallpox vaccine, Imvamune to include additional indications – specifically, monkeypox and related orthopoxvirus infections and disease in adults 18 years of age and older determined to be at high risk for exposure.
The extended approval was granted following assessment of additional clinical and non-clinical data, generated since Imvamune received approval as a smallpox vaccine by Health Canada in 2013.
